Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dasabuvir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 5/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | OGT | O15294 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.33 |
| ▸ | TUBB | P07437 | 1/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.33 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.33 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.33 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dasabuvir SCHEMBL31554838 | 0.98 | CRBN (1.00) | CRBNCYP3A4BRPF1BRD4TP53 | |
| Dasabuvir SCHEMBL351053 | 0.98 | CRBN (1.00) | CRBNCYP3A4BRPF1BRD4TP53 | |
| Dasabuvir SCHEMBL29362730 | 0.98 | CRBN (1.00) | CRBNCYP3A4BRPF1BRD4TP53 | |
| Dasabuvir SCHEMBL29838781 | 0.98 | CRBN (1.00) | CRBNCYP3A4BRPF1BRD4TP53 | |
| Dasabuvir SCHEMBL2367923 | 0.97 | CRBN (0.98) | CRBNCYP3A4BRPF1BRD4TP53 | |
| Dasabuvir SCHEMBL2368084 | 0.97 | CRBN (0.98) | CRBNCYP3A4BRPF1BRD4TP53 | |
| Dasabuvir SCHEMBL2367922 | 0.97 | CRBN (0.98) | CRBNCYP3A4BRPF1BRD4TP53 | |
| Dasabuvir SCHEMBL2368377 | 0.97 | CRBN (0.98) | CRBNCYP3A4BRPF1BRD4TP53 | |
| Dasabuvir SCHEMBL12537982 | 0.97 | CRBN (0.98) | CRBNCYP3A4BRPF1BRD4TP53 | |
| Dasabuvir SCHEMBL2367895 | 0.97 | CRBN (0.98) | CRBNCYP3A4BRPF1BRD4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140294766-A1 | Anti-Infective Agents and Uses Thereof | ABBVIE INC (US) | 2014-10-02 | — | — | US | claimed |
| EP-2368882-B1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBVIE BAHAMAS LTD (BS) | 2014-08-13 | — | — | EP | claimed |
| EP-2639226-A1 | Anti-infective pyrimidines and uses thereof | ABBOTT LABORATORIES (US) | 2013-09-18 | — | — | EP | claimed |
| US-8501238-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2013-08-06 | — | — | US | claimed |
| US-20120244119-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | claimed |
| EP-2368882-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-09-28 | — | — | EP | claimed |
| EP-2203431-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | Abbott Laboratories (US) | 2010-07-07 | — | — | EP | claimed |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | claimed |
| WO-2009039134-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | claimed |
| EP-2725015-A1 | Uracil or thymine derivative for treating hepatitis c | AbbVie Bahamas Ltd. (BS) | 2014-04-30 | — | — | EP | disclosed |
| EP-2639226-A1 | Anti-infective pyrimidines and uses thereof | ABBOTT LABORATORIES (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2368882-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244119-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | CRBN 3902/4885CYP3A4 1675/4885BRPF1 2988/4885 |
| US-20140294766-A1 | Anti-Infective Agents and Uses Thereof | MPO, SERPINB1, ELANE | CRBN 3902/4885CYP3A4 1675/4885BRPF1 2988/4885 |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | CRBN 3902/4885CYP3A4 1675/4885BRPF1 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.